Strong Revenue Growth Cubist Pharmaceuticals experienced substantial revenue growth in 2013, with total net revenues reaching over 1.1 billion dollars and blockbuster sales for its flagship product, CUBICIN, indicating a robust market presence and strong sales potential for antibiotics.

Expanding Antibiotic Pipeline The company's focus on developing four new antibiotics, including ceftolozane/tazobactam and tedizolid phosphate, offers significant sales opportunities in treating serious bacterial infections such as multidrug-resistant Gram-negative bacteria and MRSA, addressing critical unmet medical needs.

Market Focus on Antibiotics With strategic investments in antibiotics targeting hospital-acquired and complicated infections, Cubist is positioned to capture a substantial share in the growing acute care and infectious disease markets, boosting sales prospects for existing and upcoming products.

CDAD Market Potential Cubist’s ongoing efforts to re-launch DIFICID and advance surotomycin for Clostridium difficile-associated diarrhea capitalize on a large and expanding market, presenting opportunities for increased sales through improved positioning and new therapeutic options.

Focus on High-Need Areas Development of treatments for serious infections like MRSA, Pseudomonas aeruginosa, and ESBL-producing bacteria aligns with urgent healthcare needs, creating strong sales opportunities for innovative therapies in high-demand hospital settings.